Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure

International Journal of Medical Sciences

Volumn 11, Issue 11, 2014, Pages 1098-1106

  Chang, Yi Yao ^a   Chen, Aaron ^b   Wu, Xue Ming ^c   Hsu, Tse Pin ^d   Daisy, Li Yu ^e   Chen, Yenh Hsein ^d   Wu, Yen Wen ^a,f   Lin, Hung Ju ^d   Hsu, Ron Bin ^d   Lee, Chi Ming ^d   Wang, Shoei Shen ^d   Lo, Men Tzung ^g   Chen, Ming Fong ^d   Lin, Yen Hung ^d  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b Woodhull Medical and Mental Hospital   (United States)

^c TAO YUAN GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g NATIONAL CENTRAL UNIVERSITY   (Taiwan)

Author keywords

Gal 3; Heart failure; MMP 2

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COLLAGEN; GALECTIN 3; GELATINASE A; GELATINASE B; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE; PROCOLLAGEN TYPE III-N-TERMINAL PEPTIDE;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYSTOLIC HEART FAILURE; AGED; BLOOD; MIDDLE AGED; PATHOLOGY;

AGED; FEMALE; GALECTIN 3; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84906248632     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8083     Document Type: Article

References (40)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
2. Graham HK, Horn M and Trafford AW. Extracellular matrix profiles in the progression to heart failure. European Young Physiologists Symposium Keynote Lecture-Bratislava 2007. Acta Physiol (Oxf) 2008;194:3-21.
3. Yamazaki T, Lee JD, Shimizu H, Uzui H and Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 2004;6:41-5.
4. George J, Patal S, Wexler D, Roth A, Sheps D and Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005;150:484-7.
5. Rossi A, Cicoira M, Golia G, Zanolla L, Franceschini L, Marino P et al. Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis. Heart 2004;90:650-4.
6. Cicoira M, Rossi A, Bonapace S, Zanolla L, Golia G, Franceschini L et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail 2004;10:403-11.
7. Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J et al. Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail 2008;14:467-74.
8. Frantz S, Stork S, Michels K, Eigenthaler M, Ertl G, Bauersachs J et al. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 2008;10:388-95.
9. Reifenberg K, Lehr HA, Torzewski M, Steige G, Wiese E, Kupper I et al. Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice. Am J Pathol 2007;171:463-72.
10. Yndestad A, Ueland T, Oie E, Florholmen G, Halvorsen B, Attramadal H et al. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 2004;109:1379-85.
11. Bujak M and Frangogiannis NG. The role of IL-1 in the pathogenesis of heart disease. Archivum immunologiae et therapiae experimentalis 2009;57:165-76.
12. Weber KT, Gerling IC, Kiani MF, Guntaka RV, Sun Y, Ahokas RA et al. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets 2003;4:505-16.
13. de Boer RA, Voors AA, Muntendam P, van Gilst WH and van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009;11:811-7.
14. Ochieng J, Furtak V and Lukyanov P. Extracellular functions of galectin-3. Glycoconj J 2004;19:527-35.
15. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-8.
16. Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323-8.
17. McCullough PA, Olobatoke A and Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med 2011;12:200-10.
18. Grandin EW, Jarolim P, Murphy SA, Ritterova L, Cannon CP, Braunwald E et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2012;58:267-73.
19. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011;43:60-8.
20. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011;108:385-90.
21. van Kimmenade RR, Januzzi JL, Jr., Ellinor PT, Sharma UC, Bakker JA, Low AF et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-24.
22. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR and Januzzi JL. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010;12:826-32.
23. Lopez-Andres N, Rossignol P, Iraqi W, Fay R, Nuee J, Ghio S et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012;14:74-81.
24. Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clinica chimica acta; international journal of clinical chemistry 2009;409:96-9.
25. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112:e154-235.
26. Ho YL, Hsu TP, Chen CP, Lee CY, Lin YH, Hsu RB et al. Improved cost-effectiveness for management of chronic heart failure by combined home-based intervention with clinical nursing specialists. J Formos Med Assoc 2007;106:313-9.
27. de Boer RA, Yu L and van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010;7:1-8.
28. Felker GM, Fiuzat M, Shaw LK, Clare R, Whellan DJ, Bettari L et al. Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study. Circ Heart Fail 2012;5:72-8.
29. Kasper M and Hughes RC. Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. J Pathol 1996;179:309-16.
30. Lin HM, Pestell RG, Raz A and Kim HR. Galectin-3 enhances cyclin D(1) promoter activity through SP1 and a cAMP-responsive element in human breast epithelial cells. Oncogene 2002;21:8001-10.
31. Li YY, McTiernan CF and Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000;46:214-24.
32. Song YH, Cai H, Gu N, Qian CF, Cao SP and Zhao ZM. Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure. J Pharm Pharmacol 2011;63:541-9.
33. Vorovich EE, Chuai S, Li M, Averna J, Marwin V, Wolfe D et al. Comparison of matrix metalloproteinase 9 and brain natriuretic peptide as clinical biomarkers in chronic heart failure. Am Heart J 2008;155:992-7.
34. Lin YH, Lin C, Lo MT, Lin HJ, Wu YW, Hsu RB et al. The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: a potential serum marker to evaluate cardiac autonomic control and sudden cardiac death. Clin Chem Lab Med 2010;48:1821-7.
35. Zannad F, Alla F, Dousset B, Perez A and Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000;102:2700-6.
36. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arteriosclerosis, thrombosis, and vascular biology 2008;28:433-40.
37. Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D'Angelo A, Schirinzi S et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. International journal of immunopathology and pharmacology 2011;24:905-13.
38. Tsai TH, Sung PH, Chang LT, Sun CK, Yeh KH, Chung SY et al. Value and Level of Galectin-3 in Acute Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention. Journal of atherosclerosis and thrombosis 2012;19(12):1073-82.
39. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60:1249-56.
40. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL et al. The fibrosis marker galectin-3 and outcome in the general population. Journal of internal medicine 2012;272:55-64.